Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.
Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей
Chun-Hsiang Wang, Ruey-Chang Lin, Lein-Ray Mo, Kuo-Kuan Chang, Jen-Juan Kuo
Background: The present study aimed to develop an optimal model predictive of the treatment response one week after initiating antiviral therapy.
Patients and Methods: In all, 166 patients completed the treatment and were followed up for six months.
Results: A viral response was achieved in 14 (8.4%) genotype 1 (G1) and 32 (19.3%) non-genotype 1 (G0) patients at week one after initiation of therapy and 45 (27.1%) G1 and 90 (54.2%) G0 patients at week four. A sustained viral response (SVR) was achieved in 50 (30.1%) G1 and 83 (50.0%) G0 patients, in 13 (29.5%) G1 and 31 (70.5%) G0 patients whose antiviral response was achieved at one week, and in 37 G1 (32.2%) and 78 G0 (67.8%) patients whose antiviral response was achieved at four weeks. The HCV viral kinetic parameter π (i.e., 1: α, α was defined as the area under the line y [viral load]=– a[x{time}] between week 0 and week 1) was found to be the best performing test for predicting SVR (p<0.0001). Regression analysis identified π as the only independent predictor of SVR (p=0.043).
Conclusions: The use of bio-mathematical models of HCV kinetics can reliably predict SVR one week after starting therapy.